| Business Summary | | ICHOR
Corporation
was
previously
engaged,
through
an
87%
interest
in
Nazca
Holdings
Ltd.,
in
the
business
of
exploring
for
and
developing
groundwater
resources
in
Chile.
This
interest
was
disposed
in
July
2000.
In
December
2000,
the
Company
agreed
to
acquire
substantially
all
of
the
shares
of
Hippocampe
S.A.,
a
biotechnology
research
and
development
company.
Hippocampe's
current
objective
is
to
develop
vaccine
and
therapeutic
compounds
and
specific
therapies
for
certain
retroviral
diseases
or
diseases
with
a
viral
autoimmune
content.
The
first
products
and
applications
target
human
and
animal
AIDS. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Mymetics
Corporation,
through
Hippocampe
S.A.,
is
involved
in
biotechnology
research
and
development
of
human
and
veterinary
biology
and
medicine.
The
Company's
products
and
applications
target
human
and
animal
AIDS.
For
the
fiscal
year
ended
12/31/00,
revenues
decreased
9%
to
$166
thousand.
Net
loss
decreased
30%
to
$330
thousand.
Revenues
reflect
decreased
interest
income.
Lower
loss
reflects
the
inclusion
of
a
$298
thousand
gain
on
the
sale
of
a
subsidiary. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Pierre-Francois Serres, 51 | Pres,
CEO, Director | John Musacchio, 53 | CFO,
Sec., Director |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|